PF-03814735

CAT: 0804-HY-14574-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-14574-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and aurora B inhibitor with IC50s of 0.8 and 0.5 nM, respectively.
CAS Number
[942487-16-3]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Aurora Kinase; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-03814735.html
Purity
99.45
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(CNC(C)=O)N1[C@@H]2C3=C(C=C(NC4=NC(NC5CCC5)=C(C(F)(F)F)C=N4)C=C3)[C@H]1CC2
Molecular Formula
C23H25F3N6O2
Molecular Weight
474.48
Precautions
H315, H319, H335
References & Citations
[1]Jani JP, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther. 2010 Apr;9 (4) :883-94.|[2]Hook KE, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012 Mar;11 (3) :710-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Aurora A; Aurora B; VEGFR1/Flt-1

Related Products

CatalogName
HY-131972-01PF-06843195
HY-100398-01PF-04979064
HY-111512-01PF-06795071
HY-122001-01PF-05186462
HY-148531-01PF-07054894
HY-111965-01PF-06647263
HY-P991569PF-04840082
HY-170443-01PF-07265028
HY-138942-01PF-06427878
HY-135441PF-06422913

Alternative Products

CatalogName
MBS386651-01PF-03814735
165891PF 03814735
A11171-50PF-03814735 50mg
A11171-100PF-03814735 100mg
A11171-5PF-03814735 5mg
A11171-10PF-03814735 10mg
MBS579460PF-03084014 (PF-3084014)
3239/10PF 573228
4277/50PF 477736
4278/10PF 431396

Popular Products